Anti‐N and anti‐Doa immunoglobulin G alloantibody–mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC‐201: case report and review of the literature

• Published in: Transfusion (Philadelphia, Pa.) Pa.), 2019-06, Vol.59 (6), p.1907-1910
• Main Authors: Unnikrishnan, Athira, Pelletier, J. Peter R., Bari, Shahla, Zumberg, Marc, Shahmohamadi, Abbas, Spiess, Bruce D., Michael, Mary Jane, Harris, Neil, Harrell, Danielle, Mandernach, Molly W.
• Format: Article
• Language: English
• ISSN: 0041-1132; 1537-2995
• DOI: 10.1111/trf.15198

BACKGROUND Delayed hemolytic transfusion reaction (DHTR) with hyperhemolysis is a potentially fatal complication resulting from alloimmunization that can cause severe hemolysis of both transfused and intrinsic red blood cells (RBCs). Patients with sickle cell disease often receive multiple RBC units during their lifetime and thus are likely to develop alloantibodies that increase the risk for DHTR. Treatment to decrease hemolysis includes intravenous immunoglobulin (IVIG), steroids, eculizumab, rituximab, and plasmapheresis in addition to erythropoietin (EPO), intravenous (IV) iron, vitamin B12, and folate to support erythropoiesis. RBC transfusion is preferably avoided in DHTR due to an increased risk of exacerbating the hemolysis. CASE REPORT We report a rare case of anti‐N and anti‐Doa immunoglobulin (Ig)G alloantibody–mediated life‐threatening DHTR with hyperhemolysis in a patient with hemoglobin SS after RBC transfusion for acute chest syndrome who was successfully treated with eculizumab and HBOC‐201 (Hemopure) in addition to steroids, IVIG, EPO, IV iron, and vitamin B12. HBOC‐201 (Hemopure) was successfully used as a RBC alternative in this patient. CONCLUSION Anti‐N and anti‐Doa IgG alloantibodies can rarely cause severe life‐threatening DHTR with hyperhemolysis. HBOC‐201 (Hemopure) can be a lifesaving alternative in this scenario. Our report also supports the use of eculizumab in DHTR; however, prospective studies are needed to determine the appropriate dose and sequence of eculizumab administration.